[go: up one dir, main page]

MX2009007144A - Combinaciones de agente antifolato en el tratamiento de cancer. - Google Patents

Combinaciones de agente antifolato en el tratamiento de cancer.

Info

Publication number
MX2009007144A
MX2009007144A MX2009007144A MX2009007144A MX2009007144A MX 2009007144 A MX2009007144 A MX 2009007144A MX 2009007144 A MX2009007144 A MX 2009007144A MX 2009007144 A MX2009007144 A MX 2009007144A MX 2009007144 A MX2009007144 A MX 2009007144A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
certain
agent combinations
antifolate
Prior art date
Application number
MX2009007144A
Other languages
English (en)
Inventor
Charles P Theuer
Bonne Jean Adams
Original Assignee
Tracon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39775383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007144(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tracon Pharmaceuticals Inc filed Critical Tracon Pharmaceuticals Inc
Publication of MX2009007144A publication Critical patent/MX2009007144A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones y método útiles en el tratamiento de ciertos cánceres; el método incluye administrar, a un paciente que recibe un agente anticancerígeno de antifolato, metoxiamina administrado en una cantidad suficiente para mejorar o aumentar el efecto del agente anticancerígeno de antifolato; en parte, esta aplicación se basa en el reconocimiento de ciertas moléculas que se dirigen a lesiones básicas o sitios AP en la mejora de ADN, aumento o potenciar la eficacia quimioterapéutica de ciertos agentes anticancerígenos.
MX2009007144A 2006-12-29 2007-12-21 Combinaciones de agente antifolato en el tratamiento de cancer. MX2009007144A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87783606P 2006-12-29 2006-12-29
US88326607P 2007-01-03 2007-01-03
US88395907P 2007-01-08 2007-01-08
PCT/US2007/088666 WO2008083107A2 (en) 2006-12-29 2007-12-21 Antifolate agent combinations in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2009007144A true MX2009007144A (es) 2009-12-18

Family

ID=39775383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007144A MX2009007144A (es) 2006-12-29 2007-12-21 Combinaciones de agente antifolato en el tratamiento de cancer.

Country Status (15)

Country Link
US (1) US8017618B2 (es)
EP (1) EP2173333B1 (es)
JP (1) JP5249239B2 (es)
KR (1) KR101195366B1 (es)
CN (2) CN102014887A (es)
AU (1) AU2007339918B2 (es)
BR (1) BRPI0722053A2 (es)
CA (1) CA2674075C (es)
ES (1) ES2688938T3 (es)
GB (1) GB2453011B (es)
HK (1) HK1215683A1 (es)
IL (1) IL199609A0 (es)
MX (1) MX2009007144A (es)
NO (1) NO344316B1 (es)
WO (1) WO2008083107A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130030237A1 (en) * 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US10725042B2 (en) * 2012-05-22 2020-07-28 Case Western Reserve University Methods of diagnosing and treating cancer
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
EP2984184B1 (en) 2013-04-09 2020-11-25 The Board of Trustees of the University of Illionis Use of dnq or dnq-87 in combination with a parp1 inhibitor for the treatment of cancer
EP3308770A1 (en) * 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed formulation
CN108135902A (zh) * 2015-07-30 2018-06-08 爱科谱迅病理研究公司 用于最优癌症治疗的定量FR-α和GART蛋白质
CA3033077C (en) * 2016-08-12 2024-06-18 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
WO2018147437A1 (ja) * 2017-02-10 2018-08-16 学校法人神戸学院 低分子医薬化合物の経粘膜吸収促進剤
KR102040034B1 (ko) * 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
CN111954529A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
WO2019157121A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
JP7490239B2 (ja) * 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化ペメトレキセドおよびその使用
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
EP3749321A4 (en) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Gamma polyglutamated antifolates and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
WO2019157120A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
WO2019160736A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090992A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
EP3752158A4 (en) 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF
EP3752155A4 (en) 2018-02-14 2022-03-16 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMATE METHOTREXATE AND USES THEREOF

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406917B1 (en) 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
AU3386597A (en) 1996-06-11 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003066579A2 (en) * 2002-02-07 2003-08-14 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
GB2385523B (en) * 2002-02-25 2004-01-07 Ronan Anthony Byrne Descent apparatus
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
AU2004274013A1 (en) 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
BRPI0417056A (pt) 2003-12-01 2007-02-06 Kudos Pharm Ltd inibidores de reparo de dano no dna para tratamento de cáncer
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
US20070082841A1 (en) 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
CN100500215C (zh) * 2006-01-23 2009-06-17 济南帅华医药科技有限公司 含氨甲喋呤及其增效剂的缓释注射剂

Also Published As

Publication number Publication date
NO20092616L (no) 2009-09-22
CN102014887A (zh) 2011-04-13
NO344316B1 (no) 2019-11-04
WO2008083107A3 (en) 2010-01-21
JP2010538967A (ja) 2010-12-16
KR20090110843A (ko) 2009-10-22
BRPI0722053A2 (pt) 2018-04-17
CA2674075A1 (en) 2008-07-10
ES2688938T3 (es) 2018-11-07
AU2007339918B2 (en) 2011-06-02
GB2453011A (en) 2009-03-25
US8017618B2 (en) 2011-09-13
GB2453011B (en) 2010-06-23
KR101195366B1 (ko) 2012-11-21
GB0812013D0 (en) 2008-08-06
IL199609A0 (en) 2010-05-17
US20080234298A1 (en) 2008-09-25
AU2007339918A1 (en) 2008-07-10
EP2173333A2 (en) 2010-04-14
EP2173333B1 (en) 2018-06-27
WO2008083107A2 (en) 2008-07-10
HK1215683A1 (zh) 2016-09-09
JP5249239B2 (ja) 2013-07-31
CA2674075C (en) 2012-10-30
CN104958299A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
MX2009007144A (es) Combinaciones de agente antifolato en el tratamiento de cancer.
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
MX2007012817A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores.
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
EP2759302A3 (en) 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
WO2008131163A8 (en) Enzymatic anticancer therapy
WO2002078716A3 (en) Methylated promoters for intraductal treatment of breast cancer
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2006133707A3 (en) Anti-cancer combination treatment and kit-of-part
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007093373A3 (en) Branched multimeric peptides for tumor diagnosis and therapy
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008078109A3 (en) Medicament
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2007128588A3 (de) Glutadon
UA96614C2 (ru) Комбинации антифолатного агента в лечении рака
PL1803456T3 (pl) Kompozycje farmaceutyczne zawierające L-733060 do zastosowania w leczeniu guzów nowotworowych
WO2006103494A3 (en) Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
ATE499378T1 (de) Anthracyclinderivate

Legal Events

Date Code Title Description
FG Grant or registration